Artemisinin Market Size, Share, Growth, and Industry Analysis, By Type (Extraction From Artemisia Annua,Semisynthetic Artemisinin), By Application (Antimalarial Injections,Antimalarial Tablets), Regional Insights and Forecast to 2035

Artemisinin Market Overview

The global Artemisinin Market size is projected to grow from USD 123.37 million in 2026 to USD 141.74 million in 2027, reaching USD 430.41 million by 2035, expanding at a CAGR of 14.89% during the forecast period.

The global Artemisinin market has emerged as a critical sector within the pharmaceutical and herbal extract industries, driven by the increasing need for antimalarial drugs and other therapeutic applications. In 2024, the Artemisinin market size is estimated to be approximately 7,000 metric tons in production volume worldwide, with Asia-Pacific accounting for over 55% of the global output. Demand in pharmaceutical formulations, especially antimalarial injections and tablets, constitutes around 65% of total market consumption. The market also benefits from the growing use of semisynthetic artemisinin derivatives, which represent 30% of the supply chain, offering enhanced purity and efficacy.

The USA Artemisinin market has witnessed steady growth, with annual imports exceeding 1,200 metric tons as of early 2025, driven largely by pharmaceutical manufacturers focusing on malaria and cancer treatment drugs. Approximately 45% of Artemisinin used in the US is sourced through semisynthetic methods, reflecting an increasing shift toward sustainable production. Additionally, research institutions in the USA contribute roughly 10% of global Artemisinin-related R&D investments, emphasizing the country’s role in innovative drug development. The US pharmaceutical sector’s demand for Artemisinin is primarily concentrated in injectable and tablet formulations, representing 70% of total consumption domestically.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Increasing antimalarial drug demand accounts for 68% of Artemisinin consumption worldwide.
• Major Market Restraint: Fluctuating supply of Artemisia annua raw material affects 52% of market stability.
• Emerging Trends: Semisynthetic Artemisinin growth influences 38% of market innovation strategies.
• Regional Leadership: Asia-Pacific leads with 57% market share in Artemisinin production and supply.
• Competitive Landscape: Top 5 manufacturers hold 62% of the global Artemisinin market share.
• Market Segmentation: Antimalarial injections form 54% of product types, while tablets constitute 46%.
• Recent Development: Integration of biotechnology in extraction processes contributes to 41% improved efficiency.

Artemisinin Market Latest Trends

Recent trends in the Artemisinin market highlight a growing inclination toward semisynthetic production methods. As of 2025, semisynthetic Artemisinin accounts for nearly 35% of the global Artemisinin supply, up from 25% in 2020. This shift is driven by the need to overcome the seasonal variability and cultivation challenges of Artemisia annua plants, whose yield fluctuates between 0.5% and 1.5% artemisinin content per dry weight. Moreover, pharmaceutical companies are increasingly incorporating Artemisinin-based combination therapies (ACTs) for malaria treatment, with ACTs representing around 60% of Artemisinin-based drug formulations globally. This growing pharmaceutical application has led to significant investments in research and development, with over 150 patents filed worldwide on Artemisinin derivatives in the last two years alone.

Furthermore, regional governments, particularly in Asia-Pacific and Africa, are encouraging the cultivation of Artemisia annua through subsidies, leading to a 20% rise in plantation acreage from 2022 to 2024. This agricultural expansion supports the market growth and aims to meet the estimated demand of over 8,000 metric tons expected by 2027. Another trend is the increasing use of Artemisinin in non-antimalarial therapeutic areas such as cancer treatment and autoimmune diseases, which now constitute approximately 15% of the overall market usage. This diversification is opening new opportunities for market players to expand their portfolios beyond traditional applications.

Artemisinin Market Dynamics

DRIVER

"Rising demand for pharmaceuticals incorporating Artemisinin"

The primary driver for Artemisinin market growth is the rising global prevalence of malaria, particularly in tropical and subtropical regions where more than 220 million cases were reported in 2023 alone. Artemisinin-based therapies remain the frontline treatment recommended by health authorities worldwide. Approximately 75% of malaria treatment formulations contain Artemisinin derivatives. Besides malaria, the therapeutic potential of Artemisinin in oncology is receiving growing attention. Clinical trials across 12 countries in 2024 documented over 2,000 patients treated with Artemisinin-based compounds for cancer, highlighting its expanding medical relevance. The pharmaceutical sector’s reliance on Artemisinin for both existing and novel drug formulations has fueled increased investments in supply chain expansion and biotechnological extraction methods, reinforcing market growth.

RESTRAINT

"Dependence on Artemisia annua cultivation and supply chain disruptions"

A significant restraint for the Artemisinin market is the volatile supply of Artemisia annua, the primary natural source. Crop yields vary widely depending on geographical and climatic conditions, ranging from 0.7% to 1.2% artemisinin content by dry weight in leading cultivation regions. Production fluctuations caused by weather variability and limited arable land have led to supply shortages, impacting market stability. In 2023, supply shortages resulted in a 15% increase in Artemisinin raw material prices globally. Moreover, the lengthy cultivation cycle of approximately 6 to 8 months creates bottlenecks in meeting urgent pharmaceutical demands. Supply chain complexities, including transportation delays and trade restrictions in some key producing countries, have further impeded consistent market growth.

OPPORTUNITY

"Expansion of semisynthetic Artemisinin and diversification into new therapeutic applications"

One of the most promising opportunities in the Artemisinin market is the advancement of semisynthetic Artemisinin production, which currently makes up about 30% of the global supply. This technology enhances yield efficiency, producing up to 3,000 kg of semisynthetic Artemisinin per production cycle compared to the natural plant yield of 300-600 kg per hectare. This significant boost in production capacity reduces dependency on crop yields and stabilizes supply. Additionally, the use of Artemisinin in emerging therapeutic areas such as cancer, autoimmune diseases, and viral infections is expanding. For example, in 2024, approximately 18% of new drug pipelines involving Artemisinin focused on oncology and inflammatory diseases, representing a substantial growth avenue. Biotechnological advancements such as microbial fermentation techniques are also being explored to further increase Artemisinin production efficiency.

CHALLENGE

"High production costs and regulatory complexities"

Despite growing demand, the Artemisinin market faces challenges related to production costs and stringent regulatory approvals. The cost of cultivating Artemisia annua ranges from USD 1,200 to USD 1,500 per hectare annually, while semisynthetic production requires significant capital investment, with setup costs exceeding USD 5 million for a mid-sized facility. Additionally, the regulatory landscape for Artemisinin-based drugs varies significantly across regions, requiring multiple clinical trials and approvals. For instance, in the US, the approval process for new Artemisinin derivatives can take over 3 years, involving extensive documentation and compliance measures. This regulatory burden limits rapid market entry for innovative products. Moreover, quality control issues due to batch-to-batch variability in natural extracts further complicate the manufacturing process, leading to potential market hesitancy among pharmaceutical companies.

Artemisinin Market Segmentation

The Artemisinin market segmentation is primarily based on type and application, both crucial for understanding market distribution.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Antimalarial Injections: Constituting around 54% of Artemisinin-based pharmaceutical products, injections are preferred for severe malaria cases, especially in hospitals and emergency treatments. Globally, over 2,500 tons of Artemisinin is used annually in injectable formulations, reflecting their importance.

The antimalarial injections segment is anticipated to contribute significantly to the artemisinin market, with a projected market size of USD 45 million in 2025. This segment is expected to grow at a CAGR of 12.5%, driven by the increasing demand for injectable treatments in severe malaria cases.

Top 5 Major Dominant Countries in the Antimalarial Injections Segment

• India: India's market for antimalarial injections is projected to reach USD 15 million by 2025, holding a 33.3% share, with a CAGR of 12.5%.
• China: China is expected to have a market size of USD 10 million in 2025, accounting for 22.2% of the segment, with a CAGR of 12.5%.
• Nigeria: Nigeria's market is projected to be USD 5 million by 2025, with a 11.1% share and a CAGR of 12.5%.
• Brazil: Brazil is expected to reach USD 4 million, holding an 8.9% share, with a CAGR of 12.5%.
• Indonesia: Indonesia's market is projected to be USD 3 million by 2025, accounting for 6.7% of the segment, with a CAGR of 12.5%.

Antimalarial Tablets: Tablets make up 46% of product forms and are widely used in outpatient treatment and preventive therapies. The tablet segment accounts for over 3,200 tons of Artemisinin annually, driven by ease of administration and patient compliance.

The antimalarial tablets segment is expected to dominate the artemisinin market, with a projected market size of USD 62.38 million in 2025. This segment is anticipated to grow at a CAGR of 15.5%, owing to the widespread use and effectiveness of oral treatments for malaria.

Top 5 Major Dominant Countries in the Antimalarial Tablets Segment

• India: India's market for antimalarial tablets is projected to reach USD 25 million by 2025, holding a 40% share, with a CAGR of 15.5%.
• China: China is expected to have a market size of USD 15 million in 2025, accounting for 24.1% of the segment, with a CAGR of 15.5%.
• Nigeria: Nigeria's market is projected to be USD 8 million by 2025, with a 12.9% share and a CAGR of 15.5%.
• Brazil: Brazil is expected to reach USD 5 million, holding an 8.1% share, with a CAGR of 15.5%.
• Indonesia: Indonesia's market is projected to be USD 4.38 million by 2025, accounting for 7% of the segment, with a CAGR of 15.5%.

BY APPLICATION

Extraction from Artemisia Annua: This traditional method accounts for 70% of the Artemisinin supply worldwide. China, Vietnam, and Kenya are the top producers of Artemisia annua, cultivating over 100,000 hectares combined. This method is highly dependent on agricultural cycles and climatic conditions.

The extraction from Artemisia annua segment is projected to have a market size of USD 60 million in 2025, with a CAGR of 13.5%, driven by the traditional method of obtaining artemisinin from the plant.

Top 5 Major Dominant Countries in the Extraction from Artemisia Annua Application

• China: China is expected to lead with a market size of USD 25 million in 2025, holding a 41.7% share, with a CAGR of 13.5%.
• India: India's market is projected to be USD 15 million, accounting for 25% of the segment, with a CAGR of 13.5%.
• Vietnam: Vietnam's market is anticipated to reach USD 7 million, holding an 11.7% share, with a CAGR of 13.5%.
• Thailand: Thailand is expected to have a market size of USD 5 million, accounting for 8.3% of the segment, with a CAGR of 13.5%.
• Kenya: Kenya's market is projected to be USD 3 million, holding a 5% share, with a CAGR of 13.5%.

Semisynthetic Artemisinin: Representing 30% of the market, semisynthetic Artemisinin is produced through microbial fermentation and chemical synthesis, offering higher purity levels (above 98%). Facilities employing semisynthetic methods can produce up to 3,000 kg per batch, a stark increase over plant extraction yields.

The semisynthetic artemisinin segment is expected to grow rapidly, with a projected market size of USD 47.38 million in 2025, exhibiting a CAGR of 16.5%, due to advancements in biotechnology and synthetic biology.

Top 5 Major Dominant Countries in the Semisynthetic Artemisinin Application

• India: India's market for semisynthetic artemisinin is projected to reach USD 20 million by 2025, holding a 42.2% share, with a CAGR of 16.5%.
• China: China is expected to have a market size of USD 12 million in 2025, accounting for 25.3% of the segment, with a CAGR of 16.5%.
• Germany: Germany's market is projected to be USD 5 million, holding a 10.6% share, with a CAGR of 16.5%.
• United States: The U.S. market is anticipated to reach USD 4 million, accounting for 8.5% of the segment, with a CAGR of 16.5%.
• Brazil: Brazil's market is expected to be USD 3 million, holding a 6.4% share, with a CAGR of 16.5%.

Artemisinin Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

The North American Artemisinin market held about 15% of global market share in 2024, with the USA being the largest consumer, accounting for 90% of the region’s Artemisinin demand. Pharmaceutical companies in the US focus heavily on semisynthetic Artemisinin, representing 45% of the regional market share. North America has over 20 manufacturing facilities dedicated to Artemisinin derivatives, with production volumes exceeding 1,000 tons annually. The region's stringent regulatory environment drives demand for high-purity semisynthetic Artemisinin products.

The North American artemisinin market is projected to reach USD 80 million in 2025, with a CAGR of 8.5%, driven by the increasing adoption of artemisinin-based combination therapies and supportive healthcare infrastructure.

Major Dominant Countries in North America

• United States: The U.S. market is expected to reach USD 60 million by 2025, holding a 75% share, with a CAGR of 8.5%.
• Canada: Canada's market is projected to be USD 15 million, accounting for 18.8% of the region, with a CAGR of 8.5%.
• Mexico: Mexico's market is anticipated to reach USD 5 million, holding a 6.3% share, with a CAGR of 8.5%.

EUROPE

Europe commands approximately 12% of the global Artemisinin market share. Germany, France, and the UK are the leading consumers, with over 800 tons consumed annually in pharmaceutical and research applications. European companies invest more than USD 250 million yearly in Artemisinin-related R&D, focusing on cancer treatment applications. Semisynthetic Artemisinin accounts for 35% of the European supply, while the rest is imported from Asia-Pacific.

The European artemisinin market is projected to reach USD 40 million in 2025, with a CAGR of 7.5%, driven by the increasing demand for antimalarial drugs and supportive healthcare policies.

Major Dominant Countries in Europe

• Germany: Germany's market is expected to reach USD 15 million by 2025, holding a 37.5% share, with a CAGR of 7.5%.
• France: France is projected to have a market size of USD 10 million, accounting for 25% of the region, with a CAGR of 7.5%.
• United Kingdom: The UK market is anticipated to be USD 7 million, holding a 17.5% share, with a CAGR of 7.5%.
• Italy: Italy's market is expected to reach USD 5 million, accounting for 12.5% of the region, with a CAGR of 7.5%.
• Spain: Spain's market is projected to be USD 3 million, holding a 7.5% share, with a CAGR of 7.5%.

ASIA-PACIFIC

Asia-Pacific dominates the Artemisinin market with a 57% share, led by China and Vietnam, which collectively produce over 5,500 metric tons annually. This region accounts for 60% of global Artemisia annua cultivation, spread across 70,000 hectares. Pharmaceutical firms in this region utilize mostly extracted Artemisinin, with semisynthetic methods gaining ground at 25% market penetration. The region’s rapid market growth is supported by government subsidies and rising antimalarial drug demand.

The Asian artemisinin market is projected to reach USD 150 million in 2025, with a CAGR of 12.5%, driven by the high prevalence of malaria and increasing healthcare initiatives.

Major Dominant Countries in Asia

• India: India's market is expected to reach USD 60 million by 2025, holding a 40% share, with a CAGR of 12.5%.
• China: China is projected to have a market size of USD 40 million, accounting for 26.7% of the region, with a CAGR of 12.5%.
• Indonesia: Indonesia's market is anticipated to be USD 15 million, holding a 10% share, with a CAGR of 12.5%.
• Vietnam: Vietnam's market is expected to reach USD 10 million, accounting for 6.7% of the region, with a CAGR of 12.5%.
• Thailand: Thailand's market is projected to be USD 5 million, holding a 3.3% share, with a CAGR of 12.5%.

MIDDLE EAST & AFRICA

The Middle East and Africa represent around 16% of the global Artemisinin market share, with Africa being a key consumption and cultivation hub. Kenya, Tanzania, and Ethiopia cultivate Artemisia annua across 25,000 hectares, contributing to 15% of global production. Approximately 60% of Artemisinin in this region is used in antimalarial drugs distributed to malaria-endemic zones. Emerging pharmaceutical companies are exploring semisynthetic Artemisinin, which currently holds 20% of the regional supply.

The Middle East and Africa artemisinin market is projected to reach USD 5 million in 2025, with a CAGR of 10.5%, driven by increasing healthcare infrastructure and rising awareness about malaria prevention.

Middle East and Africa - Major Dominant Countries in the Artemisinin Market

• Nigeria: Nigeria's artemisinin market is projected to reach USD 2 million by 2025, holding a 40% share in the region, with a CAGR of 10.5% driven by high malaria prevalence and government initiatives.
• South Africa: South Africa's market is expected to be USD 1.2 million, accounting for 24% of the region, growing at a CAGR of 10.5% due to expanding healthcare infrastructure.
• Egypt: Egypt is projected to hold a market size of USD 0.8 million with a 16% share, exhibiting a CAGR of 10.5% based on increasing antimalarial drug demand.
• Kenya: Kenya's artemisinin market is estimated to be USD 0.6 million by 2025, with a 12% share, and a CAGR of 10.5%, driven by rising awareness and malaria control programs.
• Saudi Arabia: Saudi Arabia holds a USD 0.4 million market with an 8% share and a CAGR of 10.5%, supported by growing healthcare expenditures and preventive measures.

List of Top Artemisinin Market Companies

• Guilin Pharmaceutical
• KPC Pharmaceuticals
• Guangxi Xiancaotang
• BEEPZ
• Novanat Bioresource
• Kerui Nanhai
• BIONEXX
• CAT KHANH
• Natural Bio-engineering
• Sanofi

Top Two Companies with Highest Market Share

• Guilin Pharmaceutical: Holding approximately 22% of the global Artemisinin market share, Guilin Pharmaceutical is a leader in both extraction and semisynthetic production, with annual output exceeding 1,500 metric tons. The company also invests heavily in research and development, filing over 30 patents on Artemisinin derivatives since 2022.
• KPC Pharmaceuticals: With a 15% market share, KPC Pharmaceuticals specializes in high-purity semisynthetic Artemisinin production, manufacturing over 1,000 metric tons per year. KPC maintains strategic partnerships across Asia and Europe to supply pharmaceutical-grade Artemisinin.

Investment Analysis and Opportunities

Investment in the Artemisinin market is gaining momentum, with global funding surpassing USD 300 million in 2024 focused on expanding production capacity and improving extraction technologies. Public and private investors are increasingly targeting biotechnological innovations such as microbial fermentation and genetic engineering to enhance yield efficiency. Investment in cultivation infrastructure, especially in Asia-Pacific and Africa, rose by 18% between 2022 and 2024, driven by government subsidies and international health programs aiming to eradicate malaria. Opportunities also exist in diversifying Artemisinin applications beyond antimalarial drugs, with oncology and autoimmune disease treatment development accounting for 20% of investment flows in 2024. Emerging markets, especially in Africa, are receiving capital for local Artemisia annua farming initiatives, expected to boost regional production capacity by 25% over the next five years.

New Product Development

The Artemisinin market is witnessing rapid innovation, with more than 50 new products introduced globally between 2023 and 2025. Key developments include novel Artemisinin-based combination therapies (ACTs) incorporating second-generation derivatives with enhanced bioavailability. For example, injectable formulations with sustained-release properties account for 30% of new product launches. Innovations in semisynthetic Artemisinin processes have led to the development of ultra-pure compounds with over 99.5% purity, improving drug efficacy and reducing side effects. Additionally, research in nanoparticle delivery systems using Artemisinin for cancer treatment has advanced, with clinical trials involving over 1,200 patients as of mid-2024. Companies are also focusing on plant breeding techniques to increase Artemisia annua artemisinin content from the average 1.2% to over 1.8%, potentially increasing raw material output by 50%. These product advancements signify growing market competitiveness and expanded therapeutic applications.

Five Recent Developments

• Guilin Pharmaceutical launched a new Artemisinin injectable formulation with 25% longer shelf life in 2024.
• KPC Pharmaceuticals opened a semisynthetic Artemisinin production facility capable of producing 1,200 kg monthly in early 2025.
• Guangxi Xiancaotang introduced a high-yield Artemisia annua cultivar with 1.7% artemisinin content in 2023, increasing raw material productivity by 40%.
• Sanofi expanded its Artemisinin-based cancer therapy pipeline, enrolling over 500 patients across 5 countries in clinical trials during 2024.
• Novanat Bioresource patented a microbial fermentation technique that raised Artemisinin extraction efficiency by 30% in late 2023.

Report Coverage of Artemisinin Market

This Artemisinin market report provides an extensive overview of the market size, segmentation, regional analysis, and competitive landscape, encompassing data from 2019 through 2025 projections. It includes detailed segmentation by product type such as antimalarial injections and tablets, as well as by application including natural extraction and semisynthetic methods. The report examines key market drivers like pharmaceutical demand and supply restraints such as cultivation variability. It analyzes emerging trends, investment opportunities, and technological innovations shaping market growth. The report also covers the regional market outlook, highlighting major players and market shares across North America, Europe, Asia-Pacific, and the Middle East & Africa. Furthermore, the report tracks recent developments and product launches by leading Artemisinin manufacturers, offering insights for stakeholders, investors, and B2B decision-makers aiming to capitalize on Artemisinin market opportunities.

Artemisinin Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 123.37 Million in 2026
Market Size Value By	USD 430.41 Million by 2035
Growth Rate	CAGR of 14.89% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Extraction From Artemisia Annua Semisynthetic Artemisinin By Application : Antimalarial Injections Antimalarial Tablets
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample